Try GOLD - Free

FDA Cites Failure to Report GLP-1 Risks

The Wall Street Journal

March 11, 2026

Novo Nordisk said it is working quickly to respond to the FDA's request.

- BY ELIAS SCHISGALL

Novo Nordisk received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the company's GLP-1 treatments.

This story is from the March 11, 2026 edition of The Wall Street Journal.

Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.

Already a subscriber? Sign In